Precision Oncology in Practice: Translating Molecular Profiling into Clinical Decisions and Patient Outcomes
DOI:
https://doi.org/10.62382/jcbt.v3i3.113Keywords:
Molecular profiling, Precision oncology, Next generation sequencing, Liquid biopsy, Targeted therapy, Immunotherapy, Clinical decision-makingAbstract
Precision oncology has revolutionized the treatment of cancer through changing it from organ-based to using molecular profiling technology with associated biomarkers. In this review, we discuss the uses and applications of molecular profiling technologies such as next-generation sequencing (NGS), liquid biopsies, and multi-omics in the process of profiling cancer tumors and their associated molecular changes. This review aims to present the use of molecular profiling technologies in precision cancer care by enabling accurate diagnosis, biomarker discovery, target therapy selection, and resistance and progression monitoring of cancer therapies. We also discuss the limitations in the application of these technologies in clinical practice due to problems such as proper analysis of the data, standardization, availability, and cost. Molecular tumor boards and knowledge banks will be covered under molecular profiling technology in facilitating clinical decisions. The new developments in molecular technologies, which include those targeting single cell and spatial omics, along with the employment of AI-based analyses and adaptive trials, are described as useful instruments for improving stratification and treatment personalization. Lastly, the review describes the key obstacles that need to be overcome in order to allow wider application of precision oncology in global oncology practice.
Downloads
References
Subbiah V. Rethinking cancer drug development through tumor-agnostic precision medicine. Cancer Discovery. 2025, 15(11), 2202-2208. DOI: 10.1158/2159-8290.CD-25-1457
El-Kaream SAA, Ebied SAE, Sadek NA, Attia KA, Nadwan EA. Serum estrogen and its soluble receptor levels in egyptian patients with chronic myeloid leukemia: A case-control study. Indian Journal of Hematology and Blood Transfusion. 2022, 38(2), 246-254. DOI: 10.1007/s12288-021-01451-8
Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nature Medicine. 2022, 28(4), 658-665. DOI: 10.1038/s41591-022-01717-2
Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The future of precision oncology. International Journal of Molecular Sciences. 2023, 24(16), 12613. DOI: 10.3390/ijms241612613
Sood A, Singh G, Katoch D, Kumari L, Thakur N. Genomic profiling: A paradigm shift in precision oncology. Clinical Applications of Cancer Genetic Testing. 2025, 124-137. DOI: 10.1201/9781003542162-7
Federici G, Soddu S. Variants of uncertain significance in the era of high-throughput genome sequencing: A lesson from breast and ovary cancers. Journal of Experimental & Clinical Cancer Research. 2020, 39(1), 46. DOI: 10.1186/s13046-020-01554-6
Schlesinger JJ, Baum Miller SH, Nash K, Bruce M, Ashmead D, Shotwell MS, et al. Acoustic features of auditory medical alarms—An experimental study of alarm volume. The Journal of the Acoustical Society of America. 2018, 143(6), 3688-3697. DOI: 10.1121/1.5043396
Noller K, Botsis T, Camara PG, Ciotti L, Cooper LAD, Goecks J, et al. Informatics at the frontier of cancer research. Cancer Research. 2025, 85(16), 2967-2986. DOI: 10.1158/0008-5472.CAN-24-2829
Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): A revolutionary technology in pharmacogenomics and personalized medicine in cancer. Advances in Experimental Medicine and Biology. 2019, 1168, 9-30. DOI: 10.1007/978-3-030-24100-1_2
Farhat J, Alzyoud L, AlWahsh M, Acharjee A, Al-Omari B. Advancing Precision Medicine: The role of genetic testing and sequencing technologies in identifying biological markers for rare cancers. Cancer Medicine. 2025, 14(8), e70853. DOI: 10.1002/cam4.70853
Huang LT, Zhang SL, Han CB, Ma JT. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer. Lung Cancer. 2022, 166, 9-16. DOI: 10.1016/j.lungcan.2022.01.014
Pretelli G, Spagnolo CC, Ciappina G, Santarpia M, Pasello G. Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): New lights for an unmet medical need. International Journal of Molecular Sciences. 2023, 24(10), 8878. DOI: 10.3390/ijms24108878
Gupta M, Sherrow C, Krone ME, Blais EM, Pishvaian MJ, Petricoin EF, et al. Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: A case report and review of the literature. Journal of the National Comprehensive Cancer Network. 2021, 19(1), 10-15. DOI: 10.6004/jnccn.2020.7641
Dhillon S. Dabrafenib plus Trametinib: A review in advanced melanoma with a BRAF V600 mutation. Targeted Oncology. 2016, 11(3), 417-428. DOI: 10.1007/s11523-016-0443-8
Wang J, Song J, Liu Z, Zhang T, Liu Y. High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations. Frontiers in Oncology. 2022, 12, 1015308. DOI: 10.3389/fonc.2022.1015308
Urbanska EM, Grauslund M, Berger SMS, Costa JC, Koffeldt PR, Sørensen JB, et al. ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination—case report. Translational Lung Cancer Research. 2024, 13(9), 2453-2462. DOI: 10.21037/tlcr-24-439
Jiang Z, Zhang H, Gao Y, Sun Y. Multi-omics strategies for biomarker discovery and application in personalized oncology. Molecular Biomedicine. 2025, 6(1), 115. DOI: 10.1186/s43556-025-00340-0
Acharya D, Mukhopadhyay A. A comprehensive review of machine learning techniques for multi-omics data integration: Challenges and applications in precision oncology. Briefings in Functional Genomics. 2024, 23(5), 549-560. DOI: 10.1093/bfgp/elae013
Zhao S, Du X, Zhang Y, Bai J, Meng L, Li X, et al. Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens. BMC Cancer. 2025, 25(1), 842. DOI: 10.1186/s12885-025-14186-w
Nowacka-Zawisza M, Wiśnik E. DNA methylation and histone modifications as epigenetic regulation in prostate cancer. Oncology Reports. 2017, 38(5), 2587-2596. DOI: 10.3892/or.2017.5972
White FM, Wolf-Yadlin A. Methods for the analysis of protein phosphorylation–mediated cellular signaling networks. Annual Review of Analytical Chemistry. 2016, 9(1), 295-315. DOI: 10.1146/annurev-anchem-071015-041542
Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, et al. Small molecule metabolites: Discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy. 2023, 8(1), 132. DOI: 10.1038/s41392-023-01399-3
Mohiuddin M. Monitoring and assessment of circulating tumor DNA in cancers using ultrarapid sensitivity as an innovative practice. Health Science Reports. 2025, 8(10), e71409. DOI: 10.1002/hsr2.71409
Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: Current technology and clinical applications. Journal of Hematology & Oncology. 2022, 15(1), 131. DOI: 10.1186/s13045-022-01351-y
Capuozzo M, Ferrara F, Santorsola M, Zovi A, Ottaiano A. Circulating tumor cells as predictive and prognostic biomarkers in solid tumors. Cells. 2023, 12(22), 2590. DOI: 10.3390/cells12222590
Aredo JV, Jamali A, Zhu J, Heater N, Wakelee HA, Vaklavas C, et al. Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring. American Society of Clinical Oncology Educational Book. 2025, 45(3), e481114. DOI: 10.1200/EDBK-25-481114
Molla G, Bitew M. The future of cancer diagnosis and treatment: Unlocking the power of biomarkers and personalized molecular-targeted therapies. Journal of Molecular Pathology. 2025, 6(3), 20. DOI: 10.3390/jmp6030020
Cooper LA, Demicco EG, Saltz JH, Powell RT, Rao A, Lazar AJ. PanCancer insights from The Cancer Genome Atlas: The pathologist's perspective. The Journal of Pathology. 2018, 244(5), 512-524. DOI: 10.1002/path.5028
Batis N, Brooks JM, Payne K, Sharma N, Nankivell P, Mehanna H. Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. Advanced Drug Delivery Reviews. 2021, 176, 113854. DOI: 10.1016/j.addr.2021.113854
Zhang X, Zhang Y, Zhang G, Qiu X, Tan W, Yin X, et al. Deep learning with radiomics for disease diagnosis and treatment: Challenges and potential. Frontiers in Oncology. 2022, 12, 773840. DOI: 10.3389/fonc.2022.773840
Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: Molecular mechanisms and emerging treatment options. Cancers. 2023, 15(3), 841. DOI: 10.3390/cancers15030841
Khan MSS, Al-Suede FSR, Basheer MKA, Majid AMSA. Genomic Profiling for precision cancer therapies. Journal of Precision Biosciences. 2021, 3(1), 1-12. DOI: 10.25163/biosciences.414601
Beeler JF. Integrating diagnostic products into the drug development workflow: Applications for companion diagnostics. Biotechnology Entrepreneurship. 2020, 359-370. DOI: 10.1016/B978-0-12-815585-1.00025-5
Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis. JAMA Oncology. 2019, 5(8), 1195-1204. DOI: 10.1001/jamaoncol.2019.1549
Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients. Cancer Medicine. 2018, 7(3), 746-756. DOI: 10.1002/cam4.1372
Takahashi N, Rajapakse VN, Pongor L, Kumar S, Tlemsani C, Erwin-Cohen R, et al. Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair–deficient tumors. Cold Spring Harbor Molecular Case Studies. 2020, 6(5), a005678. DOI: 10.1101/mcs.a005678
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology. 2015, 26(2), 259-271. DOI: 10.1093/annonc/mdu450
Tejaswi L, Ramesh P, Aditya S, Raju R, Prasad TSK. Computational neoantigen prediction for cancer immunotherapy. Genes & Immunity. 2025, 26(6), 531-538. DOI: 10.1038/s41435-025-00365-z
Verma M. Unravelling immune cell signatures: CIBERSORTx-assisted construction of signature matrix from single-cell data. bioRxiv. 2024. DOI: 10.1101/2024.05.05.592045
Han XW, Zhang JY, Li WD, Huang XD, Wang XY, Wang BF, et al. The role of B2M in cancer immunotherapy resistance: Function, resistance mechanism, and reversal strategies. Frontiers in Immunology. 2025, 16, 1512509. DOI: 10.3389/fimmu.2025.1512509
Sumanasuriya S, Lambros MB, de Bono JS. Application of liquid biopsies in cancer targeted therapy. Clinical Pharmacology & Therapeutics. 2017, 102(5), 745-747. DOI: 10.1002/cpt.764
Hyväkkä A, Virtanen V, Kemppainen J, Grönroos TJ, Minn H, Sundvall M. More than meets the eye: Scientific rationale behind molecular imaging and therapeutic targeting of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer and beyond. Cancers. 2021, 13(9), 2244. DOI: 10.3390/cancers13092244
Nagy P, Papp J, Grolmusz VK, Bozsik A, Pócza T, Oláh E, et al. Comprehensive clinical genetics, molecular and pathological evaluation efficiently assist diagnostics and therapy selection in breast cancer patients with hereditary genetic background. International Journal of Molecular Sciences. 2024, 25(23), 12546. DOI: 10.3390/ijms252312546
Chakravarty D, Gao JJ, Phillips SM, Kundra R, Zhang HX, Wang JJ, et al. OncoKB: A precision oncology knowledge base. JCO Precision Oncology. 2017, 2017, PO.17.00011. DOI: 10.1200/PO.17.00011
Tack V, Dufraing K, Deans ZC, van Krieken HJ, Dequeker EMC. The ins and outs of molecular pathology reporting. Virchows Archiv: An International Journal of Pathology. 2017, 471(2), 199-207. DOI: 10.1007/s00428-017-2108-0
Bartels M, Chibaudel B, Dienstmann R, Lehtiö J, Piccolo A, Michielin O, et al. Evolving and improving the sustainability of molecular tumor boards: The value and challenges. Cancers. 2024, 16(16), 2888. DOI: 10.3390/cancers16162888
Yapa HM, MacLean EL-H, Menzies NA, Dodd PJ, Dean A, Mirzayev F, et al. Drug-resistant tuberculosis: A priority pathogen for enhanced public health research and practice. Clinical Microbiology Reviews. 2025, 38(4), e0006425. DOI: 10.1128/cmr.00064-25
Ghosh M, Lingaraju SM, Krishna CR, Balaram G, Kodandapani R, Vijay E, et al., Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: A single institutional experience. Scientific Reports. 2025, 15(1), 12455. DOI: 10.1038/s41598-025-94762-z
Deng L, Kiedrowski LA, Ravera E, Cheng H, Halmos B. Response to dual crizotinib and osimertinib treatment in a lung cancer patient with MET amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition. Journal of Thoracic Oncology. 2018, 13(9), e169-e172. DOI: 10.1016/j.jtho.2018.04.007
Haynes T, Gilbert MR, Breen K, Yang CZ. Pathways to hypermutation in high-grade gliomas: Mechanisms, syndromes, and opportunities for immunotherapy. Neuro-Oncology Advances. 2024, 6(1), vdae105. DOI: 10.1093/noajnl/vdae105
Alanazi AA, Albalawi AAS, Alatawi AK, Al Ruwaili AM, Albalawi ASF, Alrouili AW, et al. The contribution of medical laboratory specialists to evidence-based clinical decision-making. The Review of Diabetic Studies. 2024, 20(S6), 522-537. DOI: 10.70082/c6ge8f76
Lee Y, Clark EW, Milan MSD, Champagne C, Michael KS, Awad MM, et al. Turnaround time of plasma next-generation sequencing in thoracic oncology patients: A quality improvement analysis. JCO Precision Oncology. 2020, 4, 1098-1108. DOI: 10.1200/PO.20.00121
Parikh S, Bernard G, Leventer RJ, van der Knaap MS, van Hove J, Pizzino A, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Molecular Genetics and Metabolism. 2015, 114(4), 501-515. DOI: 10.1016/j.ymgme.2014.12.434
Lawson McLean A, Lawson McLean AC. Integrating shared decision-making into undergraduate oncology education: A pedagogical framework. Journal of Cancer Education. 2024, 39(4), 374-382. DOI: 10.1007/s13187-024-02419-8
Covvey JR, Kamal KM, Gorse EE, Mehta Z, Dhumal T, Heidari E, et al. Barriers and facilitators to shared decision-making in oncology: a systematic review of the literature. Supportive Care in Cancer. 2019, 27(5), 1613-1637. DOI: 10.1007/s00520-019-04675-7
Kadri S, Craven KE, Fussell AM, Gee EPS, Jordan D, Klee EW, et al. Clinical bioinformatician body of knowledge-bioinformatics and software core: A report of the association for molecular pathology. The Journal of Molecular Diagnostics. 2025, 27(7), 566-582. DOI: 10.1016/j.jmoldx.2025.04.008
Roy S, Coldren C, Karunamurthy A, Kip NS, Klee EW, Lincoln SE, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: A joint recommendation of the Association for Molecular Pathology and the College of American Pathologists. The Journal of Molecular Diagnostics. 2018, 20(1), 4-27. DOI: 10.1016/j.jmoldx.2017.11.003
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nature reviews Clinical oncology. 2018, 15(2), 81-94. DOI: 10.1038/nrclinonc.2017.166
Norris RP, Dew R, Sharp L, Greystoke A, Rice S, Johnell K, et al. Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis. BMC Medicine. 2020, 18(1), 282. DOI: 10.1186/s12916-020-01753-0
Derkyi-Kwarteng ANC, Agyepong IA, Enyimayew N, Gilson L. A narrative synthesis review of out-of-pocket payments for health services under insurance regimes: A policy implementation gap hindering universal health coverage in sub-Saharan Africa. International Journal of Health Policy and Management, 2021, 10(7), 443-461. DOI: 10.34172/ijhpm.2021.38
Balagurunathan Y, Sethuraman RR. An analysis of ethics-based foundation and regulatory issues for genomic data privacy. Journal of The Institution of Engineers (India): Series B. 2024, 105(4), 1097-1107. DOI: 10.1007/s40031-024-01058-3
Grieselhuber NR, Kodner IJ, Brown D, Yu J. Confronting the therapeutic misconception. Surgery. 2017, 162(1), 183-187. DOI: 10.1016/j.surg.2017.01.031
Ntzifa A, Lianidou E. Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis. Critical Reviews in Clinical Laboratory Sciences. 2023, 60(8), 573-594. DOI: 10.1080/10408363.2023.2230290
Sinha A, Sahoo KC, Mahapatra P, Pati S, Kshatri J, Kanungo S, et al. Capacity building models for managing multiple long-term conditions in low-and-middle-income countries: A systematic review and gap analysis. Human Resources for Health. 2025, 23(1), 38. DOI: 10.1186/s12960-025-00996-3
Vassallo V. Secondary and incidental findings in genetics: Ethical issues. University of Malta. 2023.
Qiao D, Wang RC, Wang ZX. Precision oncology: Current landscape, emerging trends, challenges, and future perspectives. Cells. 2025, 14(22), 1804. DOI: 10.3390/cells14221804
Ye JZ, Lin Y, Liao ZL, Gao X, Lu C, Lu L, et al, Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma. NPJ Precision Oncology. 2024, 8(1), 262. DOI: 10.1038/s41698-024-00752-1
Hu YH, Shen F, Yang X, Han TT, Long ZW, Wen JL, et al. Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity. Clinical Epigenetics. 2023, 15(1), 161. DOI: 10.1186/s13148-023-01574-x
Khemani B, Patil S, Kotecha K, Tanwar S. A review of graph neural networks: Concepts, architectures, techniques, challenges, datasets, applications, and future directions. Journal of Big Data. 2024, 11(1), 18. DOI: 10.1186/s40537-023-00876-4
Pinheiro CMC. Mapping the landscape of real-world evidence (RWE) guidance and initiatives across regulatory jurisdictions. University of Lisbon. 2024.
Yadav S, Mondal J, Saha M. Systems biology approaches for multi omics integration using artificial intelligence. Academia Biology. 2026, 4(1), 1-16. DOI: 10.20935/AcadBiol8077
Zhao ZX, Le JH, Fu ZJ, Yang SS, Chen YT. Cancer network pharmacology: Multi-network regulatory mechanisms and future directions. Medical Oncology. 2025, 42(7), 255. DOI: 10.1007/s12032-025-02811-4
Bao H, Yang SS, Chen XX, Dong GQ, Mao Y, Wu SY, et al. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nature Medicine. 2025, 31(8), 2737-2745. DOI: 10.1038/s41591-025-03735-2
Faisal Hamdi AI, How SH, Islam MK, Lim JCW, Stanslas J. Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: Is it clinically relevant? Expert Review of Anticancer Therapy. 2022, 22(12), 1309-1323. DOI: 10.1080/14737140.2022.2147671
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Imran khan Yousafzai, Khadija Tariq, Noor Fatima, Nadia Noreen, Eisha Rehman Kayani, Zain Ul Abidin, Aqsa Mehreen
This work is licensed under a Creative Commons Attribution 4.0 International License.
